NMS·Healthcare·$559M·#146 / 520 in Healthcare
MYGN Myriad Genetics, Inc.
59SPECULATIVE
CATEGORY BREAKDOWN
GROWTH0
QUALITY65
STABILITY83
VALUATION100
GOVERNANCE50
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
-1.6%
0
> 50% strong
Gross Margin
Revenue retained after direct costs
69.9%
100
> 50% strong
Cash Runway
Months of cash at current burn rate
999 months
100
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
57.0%
49
< 25% strong
Price / Sales
Market cap relative to trailing revenue
1.0x
100
< 3x strong
Rule of 40
Growth rate plus operating margin
-10
13
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
3.8%
30
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
+1.4%
91
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE MYGN WITH…
OR QUICK-COMPARE SECTOR PEERS
SCORE ALERT
Get notified when MYGN's score changes by 5+ points.
DATA INFO
Last updated: Jul 1, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.